He and his colleagues have succeeded in releasing NGF via pea-sized pellets implanted in the brains of test animals; since animals are not affected by Alzheimer's disease, the implants were placed in the area of the brain which, in humans, is vulnerable to the disease. Dr. Saltzman said previous attempts to deliver NGF to the brain by pumping a water-based NGF solution into the ventricle were difficult and cumbersome.
NGF has proved useful in the treatment of other diseases: It has been delivered by eye-wash to treat retinal ulcers, and by injection into the bloodstream to treat diabetic neuropathy, a peripheral nerve disease that causes loss of feeling in the extremities.
Dr. Saltzman will present his paper, BIOT 19, on Sunday, Aug. 23, from 2:30 p.m. - 2:55 p.m. at the Sheraton, Republic A, 2nd Floor.
Nancy Blount can be reached at the Press Room of the Convention Center, Room 308, from Aug. 20 to Aug. 27, Phone: (617) 351-6808, FAX: (617) 351-6820.
A nonprofit organization with a membership of more than 155,000 chemists and chemical engineers as its members, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.